Equitable Trust Co. Sells 14,670 Shares of Harrow, Inc. (NASDAQ:HROW)

Equitable Trust Co. lowered its position in shares of Harrow, Inc. (NASDAQ:HROW) by 25.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 43,555 shares of the company’s stock after selling 14,670 shares during the quarter. Equitable Trust Co. owned 0.12% of Harrow worth $1,461,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the company. State Street Corp lifted its position in shares of Harrow by 2.2% during the 3rd quarter. State Street Corp now owns 730,973 shares of the company’s stock worth $32,865,000 after buying an additional 15,554 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Harrow by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 722,730 shares of the company’s stock worth $32,500,000 after buying an additional 3,960 shares in the last quarter. Braidwell LP lifted its position in shares of Harrow by 47.9% during the 3rd quarter. Braidwell LP now owns 439,638 shares of the company’s stock worth $19,766,000 after buying an additional 142,450 shares in the last quarter. First Turn Management LLC bought a new stake in shares of Harrow in the 3rd quarter worth approximately $14,683,000. Finally, Rice Hall James & Associates LLC raised its holdings in shares of Harrow by 23.1% in the 3rd quarter. Rice Hall James & Associates LLC now owns 314,881 shares of the company’s stock worth $14,157,000 after purchasing an additional 59,019 shares during the period. Institutional investors own 72.76% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on HROW shares. B. Riley lowered their price target on shares of Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a report on Wednesday, December 4th. HC Wainwright started coverage on shares of Harrow in a report on Thursday, February 6th. They issued a “buy” rating and a $57.00 price target on the stock.

Harrow Stock Up 3.2 %

Harrow stock opened at $32.00 on Tuesday. Harrow, Inc. has a 1-year low of $9.30 and a 1-year high of $59.23. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The firm has a 50 day simple moving average of $34.78 and a 200 day simple moving average of $39.83.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.